ArticleBreast cancer (Dove Medical Press)2025
Clinical Prognosis and Nomograms for Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Patients Treated with Palbociclib and Endocrine Therapy.
Article in Breast cancer (Dove Medical Press), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Keratin 80 serves as a potential biomarker in metastatic breast cancer.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to analyze factors affecting the prognosis of patients with hormone receptor-positive (HR+) and human epidermal growth factor 2-negative (HER2-) metastatic breast cancer (MBC) treated with palbociclib and endocrine therapy (ET). Methods: Patients with HR+/HER2- MBC who were treated with palbociclib plus ET between January 2019 and December 2020 at Shandong Cancer Hospital were recruited. Clinicopathological data, treatment outcomes, and survival were from electronic medical system and telephone follow-up. Results: A total of 90 eligible patients were recruited in this study; 55 (61.11%) patients preferred chemotherapy as first treatment, and 35 (38.89%) preferred ET as first treatment. The percentages for 1st, 2nd line, and ≥3 lines applying palbociclib were 17.78%, 16.66%, and 65.56%, respectively. In the univariate analysis, multiple factors influenced the primary overall survival (pOS, from initial diagnosis of BC to death), progression-free survival (PFS), and mOS (from diagnosis of metastasis to death). Meanwhile in the multivariate analysis, pPR (progesterone receptor of primary tumor) and prior ET response were independent risk factors for pOS, PFS, and mOS. Lower pPR and prior ET resistance predicted poorer pOS, PFS, and mOS in HR+/HER2- MBC patients. Number of lines of palbociclib application was an independent risk factor for pOS and mOS and presented higher points both in the pOS and mOS nomograms, meaning that palbociclib had a more significant impact on pOS and mOS compared to other factors. The nomograms showed excellent discrimination and prediction accuracy with area under curves (AUC) of 0.974 for pOS, 0.627 for PFS, and 0.881 for mOS, respectively. Conclusion: This real-world single-center study of patients with HR+/HER2- MBC showed that early application of palbociclib combined with ET may bring better PFS, but not pOS and mOS. pPR and prior ET response were independent risk factors affecting prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.